These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31399016)

  • 1. Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg.
    Fontaine C; Claes N; Graas MP; Samani KK; Vuylsteke P; Vulsteke C
    Acta Clin Belg; 2021 Feb; 76(1):10-15. PubMed ID: 31399016
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in Dutch patients.
    Timmer-Bonte JNH; Ouwerkerk J; Faber LM; Kerkhofs LGM; Laterveer L; Ten Oever D; van Rees BP; van der Linden PW
    Neth J Med; 2020 Sep; 78(5):270-276. PubMed ID: 33093252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).
    Wolff T; Schulz H; Losem C; Reichert D; Hurtz HJ; Sandner R; Harde J; Grebhardt S; Potthoff K; Mueller U; Fietz T
    Eur J Haematol; 2019 Feb; 102(2):174-181. PubMed ID: 30347466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.
    Fietz T; Lück A; Schulz H; Harde J; Losem C; Grebhardt S; Wolff T; Potthoff K; Müller U; Zaiss M; Kurbacher CM
    Curr Med Res Opin; 2019 Jul; 35(7):1127-1138. PubMed ID: 30557099
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies.
    Gessner C; Potthoff K; Frost N
    Oncol Res Treat; 2021; 44(3):93-102. PubMed ID: 33477145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR.
    Geßner C; Fietz T; Losem C; Lück A; Schulz H; Niemeier B; Groschek M; Eschenburg H; Weide R; Kretzschmar A; Frost N; Hipp J; Harde J; Matillon CD; Grebhardt S; Potthoff K
    Curr Med Res Opin; 2022 Dec; 38(12):2191-2199. PubMed ID: 36047998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
    Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
    BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.
    Douglas AG; Schwab P; Lane D; Kennedy K; Slabaugh SL; Bowe A
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1221-1226. PubMed ID: 29172983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
    Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
    BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice.
    Holubec L; Polivka J; Lisnerova L; Kubikova T; Safanda M
    In Vivo; 2017; 31(3):303-306. PubMed ID: 28438855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
    Ludwig H; Bokemeyer C; Aapro M; Boccadoro M; Gascón P; Denhaerynck K; Krendyukov A; Abraham I; MacDonald K
    Future Oncol; 2019 Mar; 15(8):897-907. PubMed ID: 30827127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled-analysis of Lipegfilgrastim Effectiveness and Safety Among Patients With Blood Malignancies in the Real-world Setting.
    Pettengell R; Wolff T; Goehler T; Cascavilla N
    Anticancer Res; 2021 Jan; 41(1):347-354. PubMed ID: 33419830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
    Tesch H; Ulshöfer T; Vehling-Kaiser U; Ottillinger B; Bulenda D; Turner M
    Oncol Res Treat; 2015; 38(4):146-52. PubMed ID: 25877937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
    Nahon S; Rastkhah M; Ben Abdelghani M; Soumoudronga RF; Gasnereau I; Labourey JL
    Support Care Cancer; 2016 May; 24(5):1991-1998. PubMed ID: 26507190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
    Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
    Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
    Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis.
    Kurbacher CM; Fietz T; Diel IJ; Egert M; Hurtz HJ; Lück A; Weide R; Salat C; Wolff T; Zaiss M; Klare P; Losem C; Illmer T; Weißenborn G; Steffens CC; Schulze M; Tesch H; Oskay-Oezcelik G; Teichmann B; Harde J; Scheuerlein RW
    Oncol Res Treat; 2015; 38(5):221-9. PubMed ID: 25966769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
    Bondarenko IM; Bias P; Buchner A
    Support Care Cancer; 2016 Jan; 24(1):267-273. PubMed ID: 26024743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
    Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.